Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen easily beat earnings and revenue views and guided high for the current fiscal year. RGEN stock jumped Wednesday.

Repligen Earnings Easily Beat, Guidance Strong

WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights for the three - and twelve-month periods ended December 31, 2020, followed by our current financial guidance for the year 2021, and access information for today's webcast and conference call.

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results

WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST.

Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference

In the latest trading session, Repligen (RGEN) closed at $223.39, marking a +1.95% move from the previous day.

Repligen (RGEN) Outpaces Stock Market Gains: What You Should Know

Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2020. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10151931. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden. This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law. Repligen Contact: Sondra S. NewmanGlobal Head of Investor Relations(781) 419-1881investors@repligen.com

Repligen to Report Fourth Quarter and Full Year 2020 Financial Results

On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?

WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines

When it comes to coronavirus vaccines, think of Repligen as the man behind the curtain and RGEN stock as a tools powerhouse. Shares broke out of a cup base in January and hover in a buy zone.

Repligen Stock Doubled In 2020 — Why Covid Demand Is Fueling It

The tailwinds behind the company's gains aren't going anywhere.

Here's Why You Should Really Own Repligen in 2021

WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39th Annual J.P. Morgan Healthcare conference being held January 11-14.  Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Wednesday, January 13, at 9:10 a.m. EST.

Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference

The bioprocessing technology company gained momentum during the coronavirus pandemic.

Why Repligen Stock Soared 107% in 2020

AstraZeneca

LHC Group

QuidelOrtho Corp

Based on strong fundamentals, here we talk about four healthcare stocks to keep in your watchlist for 2021.

4 Healthcare Stocks to Take Care of in 2021 to Boost Portfolio

Cross Country Healthcare

NetApp

Owens Corning

Spectrum Brands Hlds

Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming releases.

Buy 5 Top Stocks with Strong Earnings Beat Prospects

WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $312.2 million, which includes the exercise in full of the underwriters' option to purchase 225,000 additional shares. The offering of the shares is expected to result in approximately $298 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen.

Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters' Option

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $271.5 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about December 10, 2020 subject to customary closing conditions. Repligen Corporation intends to use the net proceeds from this offering for working capital and other general corporate purposes. Net proceeds from this offering may also be used to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. Repligen has not entered into any agreements or commitments with respect to any acquisitions or investments at this time. J.P. Morgan Securities LLC and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Craig-Hallum Capital Group, Stephens Inc., SVB Leerink LLC and William Blair & Company, L.L.C. are acting as co-managers for the offering. These securities will be issued and sold pursuant to an automatically effective shelf registration statement (including a base prospectus) that was previously filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to this offering has been filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com and from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Repligen Corporation Prices Public Offering of Shares of Common Stock

Repligen is a "pick-and-shovel" play in the bioprocessing industry. Repligen heavily invests in single-use products for use in downstream continuous manufacturing processes, which are two of the latest trend in the bioprocessing industry.

Repligen: A Cure For COVID-19

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional 225,000 shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Repligen (RGEN) Down 6.7% Since Last Earnings Report?

Aerpio Pharmaceuticals Inc

TRACON Pharmaceuticals

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

3 Biotech Stocks to Buy on First Vaccine Approval Optimism

Repligen (RGEN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Repligen (RGEN) Looks Good: Stock Adds 6.1% in Session

IDEXX Laboratories

Veeva Systems

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why It Might Be Time To Pay Attention To These 4 Red-Hot Health Stocks

Align Technology

Insulet

ResMed

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign

The bioprocessing technology company is having a great year.

Why Shares of Repligen Soared in October

Repligen stock jumped 9% on the heels of the report to a new 52-week high of $203.90 today. And Louis Navellier sees a lot more upside for the company.

Repligen Stock: This Little-Known Biotech Posts Record Results

Repligen Corporation's (RGEN) CEO Tony Hunt on Q3 2020 Results - Earnings Call Transcript

News for Repligen Stock (RGEN)